Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May 1;80(3-4):396–402. doi: 10.1038/sj.bjc.6690369

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

N Thatcher 1, E S De Campos 1, D R Bell 2, W P Steward 3, G Varghese 4, R Morant 5, J F Vansteenkiste 6, R Rosso 7, S-B Ewers 8, E Sundal 9, E Schatzmann 10, H Stocker 10
PMCID: PMC2362337  PMID: 10408844

Abstract

Anaemia commonly occurs in cancer patients receiving chemotherapy, often necessitating blood transfusion. This multicentre study was designed to evaluate the efficacy and safety of epoetin α in preventing the decline in haemoglobin (Hb) level, and to determine whether the transfusion requirement could be reduced, in patients receiving 4–6 cycles of primarily platinum-based combination cyclic chemotherapy for small cell lung cancer (SCLC). A total of 130 non-anaemic SCLC patients were randomized to receive no additional treatment (n = 44), epoetin α 150 IU kg−1 subcutaneously (s.c.) three times a week (n = 42) or 300 IU kg−1 s.c. three times a week (n = 44). Reductions in epoetin α dosage were made during the study if Hb level increased to >15 g dl−1. The mean weekly dosage was 335 and 612 IU kg−1, respectively, in the two active treatment groups. Significantly fewer (P < 0.05) epoetin α-treated patients experienced anaemia (Hb < 10 g dl−1) during the course of chemotherapy (300 IU kg−1, 39%; 150 IU kg−1, 48%; untreated, 66%). This was reflected in the significantly lower number of treated patients transfused [300 IU kg−1, 20% (P < 0.001); 150 IU kg−1, 45% (P < 0.05); untreated, 59%]. Epoetin α was well-tolerated, and there was no evidence of sustained, clinically significant, hypertension. In summary, epoetin α is effective and well-tolerated in maintaining Hb level and reducing transfusion requirement in patients undergoing cyclic chemotherapy for SCLC. © 1999 Cancer Research Campaign

Keywords: epoetin prevents chemotherapy SCLC anaemia

Full Text

The Full Text of this article is available as a PDF (128.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer. 1993;29A Suppl 2:S2–S8. doi: 10.1016/s0959-8049(05)80281-3. [DOI] [PubMed] [Google Scholar]
  2. Baer A. N., Dessypris E. N., Goldwasser E., Krantz S. B. Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol. 1987 Aug;66(4):559–564. doi: 10.1111/j.1365-2141.1987.tb01344.x. [DOI] [PubMed] [Google Scholar]
  3. Blumberg N., Heal J. M. Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med. 1994 Apr;118(4):371–379. [PubMed] [Google Scholar]
  4. Canetta R., Rozencweig M., Carter S. K. Carboplatin: the clinical spectrum to date. Cancer Treat Rev. 1985 Sep;12 (Suppl A):125–136. doi: 10.1016/0305-7372(85)90027-1. [DOI] [PubMed] [Google Scholar]
  5. Cascinu S., Fedeli A., Fedeli S. L., Catalano G. Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study. Br J Cancer. 1993 Jan;67(1):156–158. doi: 10.1038/bjc.1993.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Case D. C., Jr, Bukowski R. M., Carey R. W., Fishkin E. H., Henry D. H., Jacobson R. J., Jones S. E., Keller A. M., Kugler J. W., Nichols C. R. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst. 1993 May 19;85(10):801–806. doi: 10.1093/jnci/85.10.801. [DOI] [PubMed] [Google Scholar]
  7. Del Mastro L., Venturini M., Lionetto R., Garrone O., Melioli G., Pasquetti W., Sertoli M. R., Bertelli G., Canavese G., Costantini M. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol. 1997 Jul;15(7):2715–2721. doi: 10.1200/JCO.1997.15.7.2715. [DOI] [PubMed] [Google Scholar]
  8. Eschbach J. W., Egrie J. C., Downing M. R., Browne J. K., Adamson J. W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987 Jan 8;316(2):73–78. doi: 10.1056/NEJM198701083160203. [DOI] [PubMed] [Google Scholar]
  9. Gebbia V., Valenza R., Rausa L. The in vitro effect of recombinant erythropoietin on cisdiamminodichloroplatinum-induced inhibition of murine erythroid stem cells. Anticancer Res. 1990 Nov-Dec;10(6):1779–1782. [PubMed] [Google Scholar]
  10. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S., Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997 Mar;15(3):1218–1234. doi: 10.1200/JCO.1997.15.3.1218. [DOI] [PubMed] [Google Scholar]
  11. Hesketh P. J., Cooley T. P., Finkel H. E., Wright J., Hesketh A. M. Treatment of advanced non-small cell lung cancer with cisplatin, 5-fluorouracil, and mitomycin C. Cancer. 1988 Oct 15;62(8):1466–1470. doi: 10.1002/1097-0142(19881015)62:8<1466::aid-cncr2820620803>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  12. Kaye S. B., Lewis C. R., Paul J., Duncan I. D., Gordon H. K., Kitchener H. C., Cruickshank D. J., Atkinson R. J., Soukop M., Rankin E. M. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 1992 Aug 8;340(8815):329–333. doi: 10.1016/0140-6736(92)91404-v. [DOI] [PubMed] [Google Scholar]
  13. Kuzur M. E., Greco F. A. Cisplatin-induced anemia. N Engl J Med. 1980 Jul 10;303(2):110–111. doi: 10.1056/NEJM198007103030215. [DOI] [PubMed] [Google Scholar]
  14. Ludwig H., Fritz E., Kotzmann H., Höcker P., Gisslinger H., Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990 Jun 14;322(24):1693–1699. doi: 10.1056/NEJM199006143222402. [DOI] [PubMed] [Google Scholar]
  15. Ludwig H., Leitgeb C., Fritz E., Krainer M., Kührer I., Kornek G., Sagaster P., Weissmann A. Erythropoietin treatment of chronic anaemia of cancer. Eur J Cancer. 1993;29A Suppl 2:S8–12. doi: 10.1016/s0959-8049(05)80282-5. [DOI] [PubMed] [Google Scholar]
  16. Ludwig H., Pecherstorfer M., Leitgeb C., Fritz E. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells. 1993 Sep;11(5):348–355. doi: 10.1002/stem.5530110502. [DOI] [PubMed] [Google Scholar]
  17. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  18. Miller C. B., Jones R. J., Piantadosi S., Abeloff M. D., Spivak J. L. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990 Jun 14;322(24):1689–1692. doi: 10.1056/NEJM199006143222401. [DOI] [PubMed] [Google Scholar]
  19. Rothmann S. A., Paul P., Weick J. K., McIntyre W. R., Fantelli F. Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells. Int J Cell Cloning. 1985 Nov;3(6):415–423. doi: 10.1002/stem.5530030607. [DOI] [PubMed] [Google Scholar]
  20. Skillings J. R., Sridhar F. G., Wong C., Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol. 1993 Feb;16(1):22–25. doi: 10.1097/00000421-199302000-00006. [DOI] [PubMed] [Google Scholar]
  21. Walker R. H. Special report: transfusion risks. Am J Clin Pathol. 1987 Sep;88(3):374–378. doi: 10.1093/ajcp/88.3.374. [DOI] [PubMed] [Google Scholar]
  22. de Campos E., Radford J., Steward W., Milroy R., Dougal M., Swindell R., Testa N., Thatcher N. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol. 1995 Jul;13(7):1623–1631. doi: 10.1200/JCO.1995.13.7.1623. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES